Drug
T3D-959 clinical trials
Keep track of what changes. Save the T3D-959 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
3 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2021 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
T3D Therapeutics, Inc. (3)
Studies
Open first, then newest update. How each study uses T3D-959 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease SubjectsNot yet recruitingPhase 2/3T3D Therapeutics, Inc.NCT06964230Written as T3D-959
- Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD SubjectsCompletedPhase 2T3D Therapeutics, Inc.NCT04251182Written as 15mg T3D-959
- Feasibility Study in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedPhase 1/2T3D Therapeutics, Inc.NCT02560753Written as T3D-959
Codes
What other systems call T3D-959 · ClinicalTrials.gg INT018633
- Wikidata Q138042831T3D-959One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q138042831 | T3D-959 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.